Marotta F, Harada M, Goh KL, Lorenzetti A, Gelosa F, Minelli E

Language: English
References: 45
Page: 268-272
PDF size: 89.51 Kb.

Text Extraction

The aim of this study was to investigate the effects of the herbal compound YHK on hepatocarcinogenesis induced by diethylntrosamine (DEN) in Sprague Dawley rats. Rats were randomly divided into 3 groups and followed up for 15 weeks. Groups 1 was given standard food and represented the healthy control. Liver preneoplastic foci were induced using the DEN method in groups 2 and 3 (20 rats each). However, group 3 was concomitantly given 50mg/kg/day of YHK. For quantitative assessment of liver preneoplastic foci, the placental form of glutathione-S-transferase (GST-P) positive foci were measured using immunohistochemical staining and image analysis. Treatment using DEN caused a significant decrease in body weight and increase in liver weight compared to the control group while concomitant supplementation with YHK prevented body weight loss and liver weight increase. As compared to DENonly treated rats, the group given YHK showed a significant decrease in the number, size and volume of GSTP-positive foci. Moreover, co-administration of YHK significantly reduced the incidence, number, size and volume of hepatocellular carcinoma. Anti-inflammatory, anti-fibrotic as well as antioxidative properties of this compound are mechanisms which are likely to be advocated for to explain its protective effect. It is concluded that herbal compound YHK by preventing hepatocarcinogenesis in DEN-induced liver preneoplastic lesions in rats has the potential to a large clinical application as a functional food.

REFERENCES

1. Sugimura T. History, present and future, of heterocyclic amines, cooked food mutagens. In “Heterocyclic Amines in Cooked Foods: Possible Human Carcinogens,” ed. R. H. Adamson, J.-Å. Gustafsson, N. Ito, M. Nagao, T. Sugimura, K. Wakabayashi and Y. Yamazoe,1995: 214-231. Princeton Scientific Publishing Co., Inc., Princeton, NJ.

2. Sugimura T. Nutrition and dietary carcinogens. Carcinogenesis 2000; 21: 387-395.

3. Yamashita K, Adachi, M, Kato S, Nakagama H, Ochiai M, Wakabayashi K, Sato S, Nagao M, Sugimura T. DNA adducts formed by 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in rat liver: doseresponse on chronic administration. Jpn J Cancer Res 1990; 81:470-476.

4. Kato T, Ohgak, H., Hasegawa H, Sato S, Takayama S, Sugimura T. Carcinogenicity in rats of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-f ]quinoxaline. Carcinogenesis 1988; 9: 71-73.

5. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. MeIQx (2-amino-3,8-dimethylimidazo [4,5-f ]quinoxaline. In “IARC Monographs on the Evaluation of Carcinogenic Risks to Humans-Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins,” 1993; 56: 211-228. IARC, Lyon.

6. Murray S, Gooderham NJ, Boobis AR, Davis DS. Detection and measurement of MeIQx in human urine after ingestion of a cooked meat meal. Carcinogenesis 1989; 10: 763-765.

7. Tannenbaum SR, Stillwell WG, Ji H, Skipper PL, Yu MC, Ross RK, Henderson BE, Turesky RJ, Gross GA. MeIQx (2-amino-3,8-dimethylimidazo [4,5-f ]quinoxaline): metabolism in humans and urinary metabolites in human populations. In: “Heterocyclic Amines in Cooked Foods: Possible Human Carcinogens,” ed. RH Adamson JÅ Gustafsson, N Ito, M Nagao, T. Sugimura K. Wakabayashi and Y Yamazoe, 1993: 197-206. Princeton Scientific Publishing Co., Inc., Princeton, NJ.

8. Ushiyama H, Wakabayashi K, Hirose M, Itoh H, Sugimura T, Nagao M. Presence of carcinogenic heterocyclic amines in urine of healthy volunteers eating normal diet, but not in patients receiving parenteral alimentation. Carcinogenesis 1991; 12: 1417-1422.

9. Totsuka Y, Fukutome K, Takahashi M, Takahashi S, Tada A, Sugimura T, Wakabayashi K. Presence of N2-(deoxyguanosin-8-yl)-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (dG-C8-MeIQx) in human tissues. Carcinogenesis 1996; 17: 1029-1034.

10. Marotta F, Rouge A, Harada M, Anzulovic H, Idéo GM, Yanaihara N, Princess G, Idéo G. Beneficial effect of a controlled Chinese herbal remedy, K-17-22, in CCl4-induced liver toxicity: an in vivo and in vitro study. Biomed Res 2001; 22:167-174.

11. Marotta F, Bertuccelli J, Albergati F, Harada M, Safran P, Yanaihara N, Idéo G. Ischemia-reperfusion liver injury: effect of a nutritional approach with K-17.22 on hepatic antioxidant defense system. Biomed Res 2001; 22: 221-227.

12. Marotta F, Lecroix P, Harada M, Masulair K, Safran P, Lorenzetti A, Ono-Nita SK, Marandola P. Liver exposure to xenobiotics: the aging factor and potentials for functional foods. Rejuven Res 2006; 1067: 408-13.

13. Harada M, Marotta F, Sha SH, Minelli E. YHK, a novel herbal remedy with effective antifibrotic action, in chronic liver disease: a pilot clinical study aiming to a successful integrative medicine development. First JSH Single Topic Conference “Therapy of viral hepatitis and prevention of hepatocellular carcinoma” November 2002: 14-15, Yamanashi, Japan.

14. Chande N, Laidlaw M, Adams P, Marotta P. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci 2006; 51: 1183-119.

15. Satoh K, Kitahara A, Satoh K, Ishikawa T, Tatematsu M, Ito N. The placental form of glutathione S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 1984; 75: 199-202.

16. Satoh K, Hatayama I, Tateoka N, Tamai K, Shimizu T, Tatematsu M, Ito N, Sato K. Transient induction of single GST-P positive hepatocytes by DEN. Carcinogenesis 1989; 10: 2107-2111.

17. Hasegawa R, Ito N. Hepatocarcinogenesis in the rat. In: Waalkes MP, Ward JM. Carcinogenesis. New York: Raven Press; 1994: 39-64.

18. Solt D, Farber E. New principle for the analysis of chemical carcinogenesis. Nature 1976; 263: 701-703.

19. Hsu SM, Raine L, Fanger H. Use of avidin–biotin–peroxidase complex (ABC) in immuno-peroxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.

20. Peacock CS, Thompson IW, Van Noorden S. Silver enhancement of polymerised diaminobenzidine: increased sensitivity for immunoperoxidase staining. J Clin Pathol 1991; 44: 756-758.

21. Pugh TD, King JH, Koen H, Nychka D, Chover J, Wahba G, Hey Y, Goldfarb S. Reliable stereological method for estimating the number of microscopic hapatocellular foci from their transection. Cancer Res 1983; 43:1261-1268.

22. Campbell HA, Pitot HC, Potter VR, Laishes BA. Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res 1982; 42: 465-472.

23. Squire RA, Levitt MH. Report of a workshop on classification of specific hepatocellular lesions in rats. Cancer Res 1975; 35: 3214-23.

24. Phillips DF. Conference explores ethics of animal research with critical thinking and balanced argument. JAMA 1996; 276: 87-8.

25. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524.

26. Hasler CM. The changing face of functional foods. J Am Coll Nutr 2000; 19(suppl. 5): 499-506.

27. Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 1996; 9: 2691-2696.

28. Yoshida Y. A non-cardiogenic type of pulmonary edema after administration of Chinese herbal medicine (shosaikoto)-a case report. Nihon Kokyuki Gakkai Zasshi 2003; 41: 300-303. in Japanese.

29. Nose M, Tamura M, Ryu N, Mizukami H, Ogihara Y. Sho-saiko-to and Saiko-keisi-to, the traditional Chinese and Japanese herbal medicines, altered hepatic drug-metabolizing enzymes in mice and rats when administered orally for a long time. J Pharm Pharmacol 2003; 55: 1419-1426.

30. Ito N, Tsuda H, Tatematsu M, Inoue T, Tagawa Y, Aoki T, Uwagawa S, Kagawa M, Ogiso T, Masui T, Imaida K, Fukushima S, Asamoto M. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rat-an approach for a new medium-term bioassay system. Carcinogenesis 1988; 9: 387-394.

31. Sato K, Kitahara A, Satoh K, Ishikawa T, Tatematsu M, Ito N. The placental form of glutathione S-transferaseas a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 1984; 75: 199-202.

32. Eaton DL, Bammler TK. Concise review of the glutathione Stransferase and their significance to toxicology. Toxicol Sci 1999; 49: 156-164.

33. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984; 5: 453-458.

34. Schulte-Hermann R, Timmermann-Trosiener I, Barthel G, Bursch W. DNA synthesis, apoptosis and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 1990; 50: 5127-5135.

35. Matsui Y, Uhara J, Satois S, Kaibori M, Yamada H, Kitade H. Improved prognosis of hepatocellular carcinoma patients when treated with functional food: a prospective cohort study. J Hepatol 2002; 37: 78-86.

36. Bass N. It could have been something they ate–functional food and the treatment of liver cancer. J Hepatol 2002; 37: 147-150.

37. Hsieh CL, Yen GC. Antioxidant actions of Du-Zhong (Eucommia ulmoides oliv.) towards oxidative damage in biomolecules. Life Sci 2000; 66: 1387-1400.

38. Zhang Y, Ye QF, Lu L, Xu XL, Ming YZ, Xiao JS. Panax notoginseng saponins preconditioning protects rat liver grafts from ischemia/reperfusion injury via an antiapoptotic pathway. Hepatobiliary Pancreat Dis Int 2005; 4: 207-212.

39. Yanez J, Vicente V, Alcaraz M, Castillo J, Benavente-Garcia O, Canteras M, Teruel JA. Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer 2004; 49(2): 191-9.

40. Induction of apoptosis in HL-60 cells treated with medicinal herbs. Nishida S, Kikuichi S, Yoshioka S, Tsubaki M, Fujii Y, Matsuda H, Kubo M, Irimajiri K. Am J Chin Med 2003; 31(4): 551-62.

41. Okamoto T, Kajino K, Hino O. Hepatoprotective drugs for the treatment of virus-induced chronic hepatitis: from hypercarcinogenic state to hypocarcinogenesis state. Jpn J Pharmacol 2001; 98:177-180.

42. Barbisan LF, Spinardi-Barbisan AL, Moreira EL, Salvadori DM, Ribeiro LR, da Eira AF, de Camargo JL. Agaricus blazer (Himematsutake) does not alter the development of rat diethylnitrosamine-initiated hepatic preneoplastic foci. Cancer Sci 2003; 94: 188-192.

43. Low-Baselli A, Huber WW, Kafer M, Bukokska K, Shulte-Hermann R, Grasl-Kraupp B. Failure to demonstrate chemoprevention by the monoterpene perillyl alcohol during early rat hepatocarcinogenesis: a cautionary note. Carcinogenesis 2000; 21: 1869-1877.

44. Shukls Y, Aora A. Enhancing effects of mustard oil on preneoplastic hepatic foci development in Wistar rats. Hum Exp Toxicol 2003; 22:51-55.

45. Breinholt VM, Molck AM, Svendsen GW, Daneshvar B, Vinggaard AM, Poulsen M, Dragsted LO. Effects of dietary antioxidants and 2-amino-3-methylimidazo[4,5-f]- quinoline (IQ) on preneoplastic lesions and on oxidative damage, hormonal status, and detoxification capacity in the rat. Food Chem Toxicol 2003; 41: 1315-23.